Lendlease

Stem Sel Srl is a spin off founded in 2013 by entrepreneurs belonging from the University of Bologna, and participated from AlmaCube Srl and investors. The business of Stem Sel is based on the development, engineering, production and commercialization of an instrumentation (and related consumables), called Celector (R). The disruptive trait of Celector (R) innovation lies on its proprietary technology for tag-less separation and selection of cells, particularly human stem cells from complex, adult "discarded" tissues (e.g. placenta, umbilical cord, lipoaspirate, dental pulp). These cells are increasingly used for cell therapy applications in regenerative medicine. Celector(R) separates, profile, characterize, counts, isolate and collect best cells without manipulation. Celector(R) is relies on a robust management of IP based on a clusters of different national and international patents on its methods, technologies, and devices for the cell fractionation process.